Patents Represented by Attorney William H. Edgerton

Find this attorney in the Justia Lawyer Directory

  • Oral compositions of proteinaceous medicaments
    Patent number: 5206219
    Abstract: Proteinaceous medicaments such as erythropoetin, insulin and calcitonin are formulated in a medium comprising a polyol pharmaceutical solvent combined as co-solvent with a lipid pharmaceutical solvent. The formulation is adapted for oral administration as a liquid as well as a filled hard or soft gelatin capsule. The preferred polyol solvent is polyethylene glycol/propylene glycol; the preferred lipid solvent is oleic acid.
    Type: Grant
    Filed: November 25, 1991
    Date of Patent: April 27, 1993
    Assignee: Applied Analytical Industries, Inc.
    Inventor: Ashok J. Desai
  • Oral liquid compositions of non-steroidal anti-inflammatory drugs
    Patent number: 5183829
    Abstract: Pharmaceutically elegant oral compositions of non-steroidal anti-inflammatory drugs or their salts are prepared by adding selected dispersing agents such as a polyvinylpyrrolidone, hydroxypropyl-methylcellulose or hydroxypropylcellulose to the NSAIDs in a medium of polyol-glycol-alcohol. The compositions offer the formation of finely dispersed active ingredients upon dispersion in gastric juice.
    Type: Grant
    Filed: September 27, 1991
    Date of Patent: February 2, 1993
    Assignee: Applied Analytical Industries, Inc.
    Inventor: Henry C. Caldwell
  • Aluminum complex of polysulfonated sucrose
    Patent number: 5084446
    Abstract: A sucralfate-like chemical compound which is free flowing but turns viscid upon contact with acid or non-acid aqueous liquid. The compound is prepared by adding an excess of aluminum chlorohydrate to sucrose octaammonium sulfate in aqueous alcohols.
    Type: Grant
    Filed: July 19, 1989
    Date of Patent: January 28, 1992
    Assignee: Applied Analytical Industries, Inc.
    Inventors: John M. Baldoni, Nick V. Lazaridis
  • Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
    Patent number: 5059626
    Abstract: A one phase, liquid composition for oral administration comprises a NSAID such as an anthranilic acid derivative plus a di- or triglyceride of a medium chain fatty acid edible oil which has the characteristics of a pharmaceutical solvent carrier as known to those skilled in the art. Other pharmaceutical additives may be optionally added. An additional stipulation is that ethanol or other monohydric alcohol solvents should not be present.
    Type: Grant
    Filed: January 30, 1991
    Date of Patent: October 22, 1991
    Assignee: Applied Analytical Industries, Inc.
    Inventors: Moo W. Park, Henry C. Caldwell
  • Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
    Patent number: 5011852
    Abstract: A one phase, liquid composition for oral administration comprises a NSAID such as an indoleacetic acid derivative or a pyrroleacetic acid derivative plus a di- or triglyceride of a medium chain fatty acid edible oil which has the characteristics of a pharmaceutical solvent carrier as known to those skilled in the art. Other pharmaceutical additives may be optionally added. An additional stipulation is that ethanol or other monohydric alcohol solvents should not be present.
    Type: Grant
    Filed: March 6, 1990
    Date of Patent: April 30, 1991
    Assignee: Applied Analytical Industries, Inc.
    Inventors: Moo K. Park, Henry C. Caldwell
  • Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
    Patent number: 4918103
    Abstract: A pharmaceutically elegant, one phase, liquid composition for oral administration comprises a NSAID such as ibuprofen plus a di- or triglyceride of a medium chain fatty acid edible oil which has the characteristics of a pharmaceutical solvent carrier as known to those skilled in the art. Other pharmaceutical additives may be optionally added. An additional stipulation is that ethanol or other monohydric alcohol solvents should not be present.
    Type: Grant
    Filed: July 25, 1988
    Date of Patent: April 17, 1990
    Assignee: Formulations Development Labs
    Inventors: Moo K. Park, Henry C. Caldwell
  • Oral liquid pharmaceutical compositions of sulindac
    Patent number: 4880835
    Abstract: Pharmaceutically elegant oral liquid compositions of sulindac are prepared using calcium sulindac in a vehicle comprising a glycol, a polyol, optional ethanol and pharmaceutical additives.
    Type: Grant
    Filed: November 3, 1988
    Date of Patent: November 14, 1989
    Assignee: Formulations Development Labs, Inc.
    Inventor: Moo K. Park
  • Feed compositions containing pyridylalkylhydrazides
    Patent number: 4668672
    Abstract: Selected pyridylalkylhydrazides are used as active ingredients in animal feed compositions and in methods for increasing the growth and feed efficiency of monogastric, meat-producing animals. A particularly useful active ingredient of this invention is 3-azabicyclo-[3.2.2]nonane-3-carbothioic acid 2-[1-(2-pyridyl)ethyl]-hydrazide.
    Type: Grant
    Filed: March 12, 1985
    Date of Patent: May 26, 1987
    Assignee: SmithKline Beckman Corporation
    Inventors: Alfred W. Chow, Thomas O. Lindsey, Winfred J. Sanders
  • Polypeptide intermediates
    Patent number: 4658015
    Abstract: Certain vasopressin-like peptides, which have an acyclic unit at position 1 and which have an .omega.-amino- or guanidinoalkyl substituent attached to the cysteine in the 6-position of the ring, have V.sub.1 -vasopressin and oxytocin antagonist activity. A species of this series of new compounds is [1-desaminopenicillamine-2-(O-ethyl-D-tyrosine)-8-(1,4-diaminobutane)-9-de sglycinamide]-vasopressin.
    Type: Grant
    Filed: April 16, 1986
    Date of Patent: April 14, 1987
    Assignee: SmithKline Beckman Corporation
    Inventors: James F. Callahan, William F. Huffman, Michael L. Moore, Nelson C. Yim
  • Cupric oxidation of 1,6-dimercapto-containing peptides
    Patent number: 4656248
    Abstract: The preparation of [1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid)-2-(O-ethyl-D-tyrosine)-4-valine-8-arginine-9-desglycine]vasopressin by oxidation of the corresponding dimercaptan is improved by using a copper II salt.
    Type: Grant
    Filed: April 23, 1985
    Date of Patent: April 7, 1987
    Assignee: SmithKline Beckman Corporation
    Inventors: Suresh M. Kalbag, Paul J. Voelker
  • Aromatic basic-tailed vasopressin antagonists
    Patent number: 4624943
    Abstract: Certain new vasopressin-like peptides which have structures characterized by having a bisaminoalkylbenzene present in the vasopressin tail at the 7- or 8-position retain vasopressin antagonist activity. A species of the invention is [1-.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid)-2-(O-ethyl)-D-tyrosine-4-valine-8-1',4'-bis(aminomethyl)benzene-9-de sglycinamide]-vasopressin.
    Type: Grant
    Filed: March 20, 1985
    Date of Patent: November 25, 1986
    Assignee: SmithKline Beckman Corporation
    Inventors: James F. Callahan, Michael L. Moore, Nelson C. Yim
  • Basic V.sub.1 -vasopressin antagonists
    Patent number: 4604378
    Abstract: Certain vasopressin-like peptides, which have an acyclic unit at position 1 and which have an .omega.-amino- or guanidinoalkyl substituent attached to the cysteine in the 6-position of the ring, have V.sub.1 -vasopressin and oxytocin antagonist activity. A species of this series of new compounds is [1-desaminopenicillamine-2-(O-ethyl-D-tyrosine)-8-(1,4-diaminobutane)-9-de sglycinamide]-vasopressin.
    Type: Grant
    Filed: November 21, 1984
    Date of Patent: August 5, 1986
    Assignee: SmithKline Beckman Corporation
    Inventors: James F. Callahan, William F. Huffman, Michael L. Moore, Nelson C. Yim
  • V1-vasopressin antagonists
    Patent number: 4599324
    Abstract: Vasopressin derivatives having V.sub.1 and oxytocin antagonist activity whose structures are characterized by a Mpa unit at position 1 and a des-Pro unit at position 7 are prepared by standard peptide synthetic methods also using an oxidative cyclization of a dimercaptan. Representative species are [1-deaminopenicillamine-2-(O-methyl)-tyrosine-7-desproline-8-arginine-9-de sglycine]vasopressin or [1-.beta.-mercaptopropionic acid-2-D-(O-ethyl)tyrosine-3-isoleucine-4-threonine-7-desproline-8-arginin e-9-desglycine]-vasopressin.
    Type: Grant
    Filed: November 21, 1984
    Date of Patent: July 8, 1986
    Assignee: SmithKline Beckman Corporation
    Inventors: Fadia E. Ali, William F. Huffman
  • .beta.-indolylalanyl or .beta.-indolylglycinyl vasopressin antagonists
    Patent number: 4597901
    Abstract: 2- or 3-.beta.-Indolylalanyl and .beta.-indolylglycyl vasopressins are prepared by standard peptide synthetic methods. These 2- or 3-TRP vasopressins have vasopressin antagonist activity.
    Type: Grant
    Filed: December 14, 1984
    Date of Patent: July 1, 1986
    Assignee: SmithKline Beckman Corporation
    Inventor: Nelson C. Yim
  • Pharmaceutical methods using 4-aminoalkyl-2(3H)-indolones
    Patent number: 4588740
    Abstract: A series of pharmaceutical compositions which contain 4-aminoalkyl-2(3H)-indolones has been demonstrated to have D.sub.2 -agonist activity useful for treating congestive heart failure and hypertension. A representative ingredient of the compositions is 4-di-n-propylaminoethyl-2(3H)-indolone or a salt thereof.
    Type: Grant
    Filed: April 5, 1984
    Date of Patent: May 13, 1986
    Assignee: SmithKline Beckman Corporation
    Inventor: Gregory Gallagher, Jr.
  • Anthelmintic benzamides
    Patent number: 4587361
    Abstract: Flukicidal N-[4-(1-phenylethenyl)phenyl]-2-hydroxy-3,5-dihalobenzamides are prepared by reacting a halosalicylic acid with a 1-(4-aminophenyl)-1-phenylethylene in the presence of a halo condensing agent. A species of the invention is N-[4-(1-phenylethenyl)phenyl]-2-hydroxy-3,5-diiodobenzamide.
    Type: Grant
    Filed: May 7, 1984
    Date of Patent: May 6, 1986
    Assignee: SmithKline Beckman Corporation
    Inventors: Alfred W. Chow, Vassilios J. Theodorides
  • Intermediates for preparing octapeptide vasopressin antagonists
    Patent number: 4587045
    Abstract: Certain octapeptides, which have structures characterized by being a six unit cyclic peptide ring with a dipeptide tail which lacks a glycine unit at position 9, have potent vasopressin antagonist activity. The compounds here claimed are in general characterized by having an amino acid unit at position 4 which is other than valine. An important species of the group is [1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid)-2-(O-ethyl-D-tyrosine)-4-.alpha.-aminobutyric acid-8-arginine-9-desglycine]vasopressin.
    Type: Grant
    Filed: May 16, 1985
    Date of Patent: May 6, 1986
    Assignee: SmithKline Beckman Corporation
    Inventors: William F. Huffman, Michael L. Moore
  • Intermediates for preparing secondary amines
    Patent number: 4579972
    Abstract: New intermediates and processes for preparing 6-halo-7,8-dihydroxy-1-(p-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepi nes involve the reaction of a p-methoxyphenylglyoxal, lower alkyl hemimercaptal with a 2-chloro-3,4-dimethoxyphenethylamine, followed by a borohydride reduction.
    Type: Grant
    Filed: June 28, 1985
    Date of Patent: April 1, 1986
    Assignee: SmithKline Beckman Corporation
    Inventors: Kathleen L. Wert, Alan W. Tremper
  • Delayed action assembly
    Patent number: 4564363
    Abstract: A device for effecting the delayed release of an active ingredient comprises a container and, within, a dispersible unit of ingredient, a removable closure and a electrical control circuit for removal of said closure at a designated time to release the active ingredient. Several assemblies are combined to control the administration of veterinary medicaments to ruminant animals as a specific application of the invention.
    Type: Grant
    Filed: July 13, 1983
    Date of Patent: January 14, 1986
    Assignee: SmithKline Beckman Corporation
    Inventors: Brian G. Bagnall, Robert J. Gyurik
  • 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones
    Patent number: 4554284
    Abstract: Certain aminoethyl substituted 1,3-benzthiazol- and 1,3-benzoxazol-2(3H)-ones are D.sub.2 -dopamine agonists. These compounds are prepared by reacting an appropriate o-aminophenol or thiophenol with phosgene.
    Type: Grant
    Filed: September 12, 1984
    Date of Patent: November 19, 1985
    Assignee: Smithkline Beckman Corporation
    Inventors: Orum D. Stringer, Joseph Weinstock